Biotech Values

[thad_1010]

dr bio...you are assuming that CAMH's technology will remain static. CAMH has a clear lead and, in my opinion, will be able to financially capitalize on their hard work and decade long fight for recognition and approval of their technology before they face any true competition. And they made it clear doing the annual meeting that research and development on other T wave alternan oriented interventions continues....St Jude's is on board and the possibilities of MTWA risk stratification for those at risk for sudden cardiac death extend well beyond what most people new to CAMH envision. Richard Cohen and Ali Hagashi-Mood, the CMO and CTO of CAMH, are brilliant scientists and understand the full implications of this technology. Of course, nothing is ever guaranteed in the world of med or biotech, but in my opinion, CAMH has the technology, the forward vision, the management and the ICD industry support (finally) to expand what many believe to be a potentially life saving screening and excellent risk stratification tool...

thad